Gigantism

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 12, 1999, Pages 4379-4384

  Eugster, Erica A ^a,b   Pescovitz, Ora H ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; GROWTH HORMONE; OCTREOTIDE; PROTEIN G; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE;

CHROMOSOME 11Q; CLINICAL FEATURE; GIGANTISM; HETEROZYGOSITY LOSS; HUMAN; HYPOPHYSIS ADENOMA; LABORATORY TEST; MULTIPLE ENDOCRINE NEOPLASIA; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT;

EID: 0033305728     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.84.12.6222     Document Type: Note

References (53)

1. Hypopituitarism beginning in infancy: The Alton giant
2. Overgrowth, section II
3. Pituitary gigantism: A disabling condition
4. Gigantism due to pituitary mammosomatotroph hyperplasia
5. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation
6. Pituitary gigantism caused by growth hormone excess from infancy
7. Acromegaly: An epidemiological study
8. Clonal origin of pituitary adenomas
9. Overexpression of the growth hormone-releasing hormone gene in acromegaly-associated pituitary tumors
10. Pituitary somatotroph adenoma producing growth hormone (GH)-releasing hormone (GHRH) with an elevated plasma GHRH concentration: A model case for autocrine and paracrine regulation of GH secretion by GHRH
11. The cytogenesis and pathogenesis of pituitary adenomas
12. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome
13. Severe endocrine and non-endocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein Gsα
14. Gsα mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year-old boy with McCune-Albright syndrome
15. Genetic basis of endocrine disease. Pituitary tumor pathogenesis
16. GTPase inhibitng mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumors
17. Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1
18. Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene
19. Inactivation of the tumor suppressor gene on 11q13 in brothers with familial acrogigantism without multiple endocrine neoplasia type 1
20. Molecular genetic studies of sporadic pituitary tumors
21. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker
22. Mammosomatotroph adenoma of the pituitary associated with gigantism and hyperprolactinemia. A morphological study including immunoelectron microscopy
23. A case for hypothalamic acromegaly: A clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor
24. Intrasellar gangliocytoma containing gastrin and growth hormone-releasing hormone associated with a growth hormone-secreting pituitary adenoma
25. Central neurocytoma presenting with gigantism: Case report
26. Growth hormone-releasing hormone-producing tumors: Clinical, biochemical, and morphological manifestations
27. Ectopic production by a malignant lymphoma causing acromegaly: Evidence for auto/paracrine growth
28. Hypothalamic mass and gigantism in neurofibromatosis: Treatment with bromocriptine
29. Growth hormone excess in a child with neurofibromatosis type I and optic pathway tumor: A patient report
30. Optic pathway glioma infiltrating into somatoststinergic pathways in a young boy with gigantism
31. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes
32. Expression of human growth hormone-releasing factor in transgenic mice results in increased somatic growth
33. Histopathology assoicated with elevated levels of growth hormone and insulin-like growth factor 1 in transgenic mice
34. Acromegaly in an infant
35. Acromegaly. Clinical and biochemical features in 500 patients
36. An audit of outcome of treatment in acromegaly
37. Remission of polycythemia vera after surgical cure of acromegaly
38. Retinal changes mimicking diabetic retinopathy in two nondiabetic, growth hormone-treated patients
39. Plasma insulin-like growth factor-1/somatomedin-C in acromegaly: Correlation with the degree of growth hormone hypersecretion
40. Serum insulin-like growth factor I in 1030 healthy children, adolescents and adults: Relation to age, sex, stage of puberty, testicular size, and body mass index
41. Serum levels of insulin-like growth factor (IGF) and IGF binding protein in constitutionally tall children and adolescents
42. Twenty-four-hour secretion of growth hormone (GH), insulin-like growth factors-1 and 11 (IGF-I, -II), prolactin (PRL) and thyrotropin (TSH) in young adults of normal and tall stature
43. Sex steroid treatment of constitutionally tall stature
44. Psychological indications for treatment of tall stature in adolescent girls
45. Outcome in tall stature: Final height and psychological aspects in 220 patients with and without treatment
46. Pituitary gigantism
47. Radiation therapy of acromegaly
48. Somatostatin analogs in the treatment of acromegaly
49. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide
50. Long-acting lantreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid
51. Long-term treatment of gigantism with combination octreotide and bromocriptine in a child with McCune-Albright syndrome
52. Suppression of growth hormone (GH) hypersecretion due to ectopic GH-releasing hormone (GHRH) by a selective GHRH antagonist
53. Treatment of acromegaly with B2036-PEG, a growth hormone receptor antagonist